Back to discover
Drug

Arginine

In clinical development
Emerging researchLate-stage developmentRising momentum
Also known as (2S)-2-amino-5-(carbamimidamido)pentanoic acid, (2S)-2-amino-5-guanidinopentanoic acid, (S)-2-Amino-5-guanidinovaleric acid, (S)-2-amino-5-guanidinopentanoic acid+47 more

(2S)-2-amino-5-(carbamimidamido)pentanoic acid, (2S)-2-amino-5-guanidinopentanoic acid, (S)-2-Amino-5-guanidinovaleric acid, (S)-2-amino-5-guanidinopentanoic acid, Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn-HBC 7 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Aminosyn-PF 7%, Arg, CanineAid, Clinisol 15, EquineAid, FelineAid, Freamine III 10, Hepatamine 8, Hepatasol, L-(+)-Arginine, L-Arg, L-Arginin, L-Arginine, Plenamine, PremaSol, ProSol, ProcalAmine 3, SwineAid, Travasol 10, Travasol 10%, Trophamine, Trophamine 10 %, Trophamine 6 %, Arginina, Arginine Hydrochloride, Clinimix 4.25/10, Clinimix 4.25/25, Clinimix 4.25/5, Clinimix 5/15, Clinimix 5/20, Clinimix 5/25, Clinimix E 2.75/5, Clinimix E 4.25/10, Clinimix E 4.25/5, Clinimix E 5/15, Clinimix E 5/20, Clinimix E 5/25.

RxNorm1091ChEMBLCHEMBL1485UNII94ZLA3W45F
5
Research papers
7
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Arginine Therapy for the Treatment of Vaso-Occlusive Events in Children With Severe Sickle Cell Disease

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Role of Decreased Nitric Oxide in the Tonic Elevation of Resting Sympathetic Nerve Activity in Chronic Kidney Disease Patients

Clinical trial2026-06-18Results expected Q4 2026 · ClinicalTrials.gov

Prospective Open-Label Pilot Study of Arginine Replacement Therapy in Children Hospitalized With COVID-19

Clinical trial2026-04-15Results expected Q2 2028 · ClinicalTrials.gov

The Effects of ATLAS (Arginine Tetrahydrobiopterin L-Ascorbate) Therapy on Nitric Oxide Bioavailability and Pain-free Walking in Patients With Intermittent Claudication

Clinical trial2026-04-15Results expected Q3 2027 · ClinicalTrials.gov

Phase 1 Randomized Clinical Trial of Arginine Hydrochloride Administration to Reduce Duration of Diabetic Ketoacidosis in Patients With Type 2 Diabetes

Clinical trial2026-02-12Results expected Q4 2027 · ClinicalTrials.gov

Efficacy of L- Arginine Versus Sildenafil in Management of Idiopathic Oligohydramnios

Clinical trial2025-09-15Primary completion · ClinicalTrials.gov

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE): an Invesitgator-initiated, Open-label, Multicenter, Randomized Controlled Trial

Clinical trial2025-08-26Results expected Q2 2027 · ClinicalTrials.gov

Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study

Clinical trial2025-02-01Completed · ClinicalTrials.gov

Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain.

Research2020-09-01Blood

Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.

Research2020-08-03Nature medicine

Myeloid Cell-Derived Arginase in Cancer Immune Response.

Research2020-05-15Frontiers in immunology

Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.

Research2017-12-19Journal for immunotherapy of cancer

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Arginine
Aliases & brands
(2S)-2-amino-5-(carbamimidamido)pentanoic acid(2S)-2-amino-5-guanidinopentanoic acid(S)-2-Amino-5-guanidinovaleric acid(S)-2-amino-5-guanidinopentanoic acidAminosyn 10%, Sulfite-FreeAminosyn 3.5 % M, Sulfite FreeAminosyn 8.5 % with Electrolytes, Sulfite-FreeAminosyn 8.5%, Sulfite-FreeAminosyn II 10 %Aminosyn II 15%Aminosyn II 8.5 % with Electrolytes, Sulfite-FreeAminosyn II 8.5 %, Sulfite-FreeAminosyn-HBC 7 %, Sulfite-FreeAminosyn-PF 10 %, Sulfite-FreeAminosyn-PF 7%ArgCanineAidClinisol 15EquineAidFelineAidFreamine III 10Hepatamine 8HepatasolL-(+)-ArginineL-ArgL-ArgininL-ArgininePlenaminePremaSolProSolProcalAmine 3SwineAidTravasol 10Travasol 10%TrophamineTrophamine 10 %Trophamine 6 %ArgininaArginine HydrochlorideClinimix 4.25/10Clinimix 4.25/25Clinimix 4.25/5Clinimix 5/15Clinimix 5/20Clinimix 5/25Clinimix E 2.75/5Clinimix E 4.25/10Clinimix E 4.25/5Clinimix E 5/15Clinimix E 5/20Clinimix E 5/25
RxNorm CUI
1091
ChEMBL ID
CHEMBL1485
UNII
94ZLA3W45F

Clinical trials

68 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
68
registered trials across all phases
LATEST COMPLETION 2025
7
Active studies
5
Recruiting
35
Late-stage (III+)
42
Completed
19
Discontinued
PHASE DISTRIBUTIONn = 68
Early Phase 11Phase 19Phase 1 / 23Phase 220Phase 2 / 32Phase 315Phase 410Phase N / A8

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Role of Decreased Nitric Oxide in the Tonic Elevation of Resting Sympathetic Nerve Activity in Chronic Kidney Disease Patients

Active, not recruitingPH IVThe University of Texas at Arlingtonn=152026

Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study

CompletedPH IVFayoum University Hospitaln=1802025

L-Arginine Role for Stone Lower Ureter : A Randomized Control Study

CompletedPH IVSohag Universityn=1532024

Comparative Clinical Study Evaluating the Effect of L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension

Unknown statusPH IVSherief Abd-Elsalamn=602023

The Effect of Orally Administered L- Arginine on Quadriceps Strenght in Healthy Smokers

Unknown statusPH IVGoranka Radmilovićn=1632022

Recent completions

Trials that read out recently, adding to the completed evidence base.

Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study

CompletedPH IVFayoum University Hospitaln=1802025

Improving Quality of Life and Daily Life Activities With Bioarginine in Patients With COPD: a Multicenter, Randomized, Controlled, Proof of Concept Study

CompletedN/AUniversity of Milann=1532024

Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

CompletedPH IIITanta Universityn=502024

L-Arginine Role for Stone Lower Ureter : A Randomized Control Study

CompletedPH IVSohag Universityn=1532024

Multicenter, Open Label Trial to Investigate the Efficacy and Safety of a Single Oral Dose of 1.0 mg/kg Macimorelin Acetate as Growth Hormone Stimulation Test (GHST) in Pediatric Patients With Suspected Growth Hormone Deficiency (GHD)

CompletedPH IIIAEterna Zentarisn=1012024

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

CompletedPH IThe University of Texas at Arlingtonn=192023

Research activity

5 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19982020
Major research themes1
Mutation, Missense1
Journals, researchers & institutions
Top journals
  • Blood1
  • Frontiers in immunology1
  • Journal for immunotherapy of cancer1
  • Nature medicine1
  • The Biochemical journal1
Leading researchers
  • Ariey F1
  • Bennett MK1
  • Brown LAS1
  • Campagne P1
  • Chen J1
  • Criscuolo A1
  • Dampier CD1
  • Emberley E1
Leading institutions
free-text, unnormalised
  • Centre of Preclinical Research1
  • Columbia University Irving Medical Center1
  • Emory University School of Medicine1
  • Institut Cochin1
  • Laboratory of Experimental Medicine1
  • Laboratory of Neurobiology BRAINCITY1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas
Neoplasms2

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Artemisinin

Studied across 2 of the same disease areas as Arginine in the shared literature.

2 shared diseases1 shared paper
Histidine

Studied across 2 of the same disease areas as Arginine in the shared literature.

2 shared diseases1 shared paper
Nitric Oxide

Studied across the same disease area as Arginine in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials